Sign up now for a $15 rebate!*

*Restrictions apply

Pet Parents

If your happy, active dog is acting anxious or seems less energetic, it could be due to arthritis. Ask your veterinarian about a treatment option that may help.

WHY ADEQUAN CANINE

Veterinarians

Arthritis can affect dogs at any age. Diagnosing and treating it early can help improve your patients’ activity level over their lifetime.

SEE WHY IT MATTERS

Committed to Dogs

Committed to improving the lives of dogs to help create more everyday adventures.

TELL ME MORE

When pain management isn't enough

Reducing joint pain for dogs with arthritis can help get them moving again, but only Adequan® Canine (polysulfated glycosaminoglycan) also proactively treats the disease.

Adequan Canine offers proven relief and reliable protection that may help to: 1

RESTORE

joint lubrication

RELIEVE

inflammation

RENEW

the building blocks
of healthy cartilage
The specific mechanism of action of Adequan® in canine joints is not known.1

Join our community. Get a $15 rebate.

Sign up today and save $15 on Adequan® Canine (polysulfated glycosaminoglycan). You'll receive exclusive offers, rebates, and joint health tips to help keep your dog moving for a lifetime of adventures.

SIGN UP NOW

Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS AND USAGE
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information.

A multimodal approach can help keep dogs moving forward

Adequan Canine is different than other treatment options because it’s the only FDA-approved drug that has been shown to slow down and even reverse cartilage deterioration in a dog’s joints.1

Creating a personalized treatment plan for dogs with arthritis can make a big difference in their active lifestyle. Adequan Canine can be prescribed as part of a multimodal approach along with NSAIDs, joint supplements, exercise, weight control and adjunct therapy to help promote joint health.

Protect cartilage before it wears away for good

Arthritis is a progressive disease that can start within a dog's first year of life.2 Over time, the cartilage in a dog’s joints wears away—and once this happens, it can’t be restored.

Starting treatment early with Adequan Canine can help slow the progression of arthritis and may lead to many more active years together. The specific mechanism of action of Adequan® in canine joints is not known.1

“The benefit of Adequan Canine is that we can use it early on in the disease process and treat these animals and make a lasting impact.”

Bryan T. Torres
DVM, PhD, DACVS-SA, DACVSMR
Dr. Torres is a paid consultant for American Regent Animal Health.

Advancing joint care for dogs & horses

For more than 30 years, veterinarians have relied on the American Regent Animal Health family of products to provide solutions that help support joint health in their patients. Our mission is to champion the long-term well-being and mobility of animals, from top athletes to family companions.

  1. Adequan® Canine (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
  2. Mele E. Epidemiology of Osteoarthritis. Veterinary Focus 17, 4-10 (2007).